Leflunomide blocks autoimmune antibodies to reduce inflammation and improve mobility for people who live with rheumatoid arthritis.
The generic version of Arava has the same chemical makeup as the original Arava. Sanofi holds the original Arava patent.
"The Arava authorized generic assures patients that they receive the same quality treatment of the original drug," Dr. Cary Yonce, vice president for general therapeutics and life-cycle management at Sanofi, said. "We are committed to making authorized generics like Arava available and affordable to patients who need them."
Rheumatoid arthritis is a chronic disease. The symptoms of RA can be lessened with treatments. Disease-modifying anti-rheumatic drugs such as Arava assist in reducing signs and symptoms, inhibit structural damage and improve physical function.
"More than 1.5 million Americans live with rheumatoid arthritis," Dr. Paul Chew, global chief medical officer at Sanofi, said. "RA can cause swelling, pain and deformity in your joints, making simple tasks like getting out of a car or buttoning a shirt difficult. We want to lessen that burden for people living with RA."
Winthrop delivers affordable solutions to the health care community by transforming Sanofi's branded products into authorized generics.
Alerts Sign-up